Factors contributing to muscle wasting and dysfunction in COPD patients by Wüst, Rob CI & Degens, Hans
© 2007 Dove Medical Press Limited.   All rights reserved
International Journal of COPD 2007:2(3) 289–300 289
REVIEW
Factors contributing to muscle wasting 
and dysfunction in COPD patients
Rob CI Wüst
Hans Degens
Institute for Biophysical and Clinical 
Research into Human Movement 
(IRM), Manchester Metropolitan 
University, Cheshire, United Kingdom
Correspondence: Rob Wüst
Institute for Biophysical and Clinical 
Research into Human Movement, 
Manchester Metropolitan University, 
Hassall Road, Alsager, Cheshire ST7 2HL, 
United Kingdom
Tel +44 161 247 5336
Fax +44 161 247 6375
Email r.wust@mmu.ac.uk
Abstract: Many patients with chronic obstructive pulmonary disease (COPD) suffer from 
exercise intolerance. In about 40% of the patients exercise capacity is limited by alterations 
in skeletal muscle rather than pulmonary problems. Indeed, COPD is often associated with 
muscle wasting and a slow-to-fast shift in ﬁ  ber type composition resulting in weakness and 
an earlier onset of muscle fatigue, respectively. Clearly, limiting muscle wasting during 
COPD beneﬁ  ts the patient by improving the quality of life and also the chance of survival. 
To successfully combat muscle wasting and remodeling during COPD a clear understanding 
of the causes and mechanisms is needed. Disuse, hypoxemia, malnutrition, oxidative stress 
and systemic inﬂ  ammation may all cause muscle atrophy. Particularly when systemic inﬂ  am-
mation is elevated muscle wasting becomes a serious complication. The muscle wasting 
may at least partly be due to an increased activity of the ubiquitin proteasome pathway and 
apoptosis. However, it might well be that an impaired regenerative potential of the muscle 
rather than the increased protein degradation is the crucial factor in the loss of muscle mass 
during COPD with a high degree of systemic inﬂ  ammation. Finally, we brieﬂ  y discuss the 
various treatments and rehabilitation strategies available to control muscle wasting and fatigue 
in patients with COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and death 
throughout the world. The disease is mainly caused by smoking, but environmental 
pollution and α1–antritrypsin deﬁ  ciency may also cause the development of COPD 
(Petty 2006). In 2000 about 16 million people suffered from COPD in the USA alone 
(Mannino et al 2002) with the number of women suffering from this disorder increas-
ing (Casaburi 2001). The disease is progressive, but the severity and progress can be 
moderated by actions such as smoking cessation, careful management of infections 
and appropriate rehabilitation (ATS/ERS 1999; Faulkner et al 2006).
One of the major problems of patients with COPD is exercise intolerance (Gosker 
et al 2000; Aliverti and Macklem 2001; Casaburi 2001). Although the disease is 
characterized by reduced maximal expiratory ﬂ  ow (ATS/ERS 1999; Faulkner et al 
2006), FEV1 in COPD correlates poorly with exercise capacity (Killian et al 1992; 
Gosselink et al 1996; Engelen et al 2000; Gosker, Lencer et al 2003). Likewise, in 
single and double lung transplants, exercise capacity did improve after surgery, but 
was still lower than normal (Ambrosino et al 1996) indicating that factors other than 
lung function alone limited exercise capacity (Evans et al 1997). Also in patients 
with COPD who did not undergo a lung-transplantation, evidence that the exercise 
intolerance is not only related to a reduced lung function, but also to skeletal muscle 
dysfunction is growing (Schols et al 1991; Gosselink et al 1996; Gosker, Lencer 
et al 2003). The importance of skeletal muscle dysfunction may increase over time International Journal of COPD 2007:2(3) 290
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as the deterioration in exercise capacity is uncoupled from 
the progression of airﬂ  ow limitation (Oga et al 2005). 
It is important, therefore, to know how muscle function 
is affected, to identify the factors that contribute to the 
muscle dysfunction and the mechanism of muscle wasting 
in COPD so as to improve the management of the disease. 
Such knowledge may also have wider implications since 
COPD is one of a number of common disorders, includ-
ing chronic heart failure (Gosker et al 2000) and cancer 
(Tisdale 2005), where muscle dysfunction and wasting 
are serious complications and may be brought about by 
similar underlying mechanisms. This review will focus on 
the changes in peripheral skeletal muscle structure, func-
tion and metabolism in COPD and discuss some of the 
potential underlying factors and mechanisms contributing 
to the observed muscle wasting and dysfunction.
The relation between muscle 
structure and function in COPD
Muscle weakness and loss of muscle mass
A loss of skeletal muscle mass is a common observation 
in patients with COPD and may not only lead to muscle 
weakness (Schols et al 1993; Gosselink et al 1996; Bernard 
et al 1998; Engelen et al 2000), but is also associated with 
an increased mortality of patients with COPD. Marquis and 
colleagues (Marquis et al 2002) reported that 50% of their 
patients with a FEV1 predicted 25% and a mid-thigh cross-
sectional area (CSA) 70 cm2 died within 3 years, compared 
to only 12% of patients with a mid-thigh CSA 70 cm2. 
Schols and colleagues (Schols et al 1993) found that about 
half of the patients with mild to severe COPD had a reduced 
body weight, which could be related to both a loss of muscle 
and adipose tissue. Since lean tissue depletion could even 
occur in overweight patients the prevalence of muscle wast-
ing might be even higher (De Benedetto et al 2000).
Muscle atrophy occurs when the balance of protein 
synthesis and degradation shifts to net protein breakdown. 
Most of the research on muscle wasting in chronic diseases 
has focused on protein degradation pathways. For an exten-
sive discussion of the molecular and cellular mechanisms 
involved in protein degradation, such as the ubiquitin-
proteosome pathway, we refer the reader to several excellent 
reviews on this subject (Jagoe and Engelen 2003; Kandarian 
and Jackman 2006; Saini et al 2006).
Besides an increased rate of protein degradation, also a 
decreased rate of protein synthesis contributes to the muscle 
wasting in many chronic diseases (Rennie et al 1983). This 
may be a consequence of systemic inﬂ  ammation that often 
occurs in patients with COPD (Gan et al 2004). Indeed, 
recent studies indicate that the regenerative capacity of 
skeletal muscle is impaired in mice with elevated circulat-
ing tumor necrosis factor-α (TNF-α) levels (Guttridge et al 
2000; Langen et al 2004, 2006). Furthermore, testosterone, 
an anabolic hormone, levels were lower in COPD patients 
(Casaburi 1998; Casaburi et al 2004; Van Vliet et al 2005). 
The lower testosterone levels were associated with muscle 
weakness (Van Vliet et al 2005). It has been speculated 
that chronic hypoxia (Aasebo et al 1993) and corticosteroid 
therapy (Kamischke et al 1998) contribute to low testosterone 
levels. It is equivocal whether insulin-like growth factor-I 
(IGF-1), which mediates muscle growth, is elevated or 
reduced in COPD patients (Creutzberg and Casaburi 2003). 
Also, human studies of myostatin, a hormone that is produced 
in the muscle and suppresses muscle growth by inhibiting 
satellite cell activity, are scarce and its role in muscle wasting 
in COPD is unknown (Jespersen et al 2006). Clearly, more 
studies are necessary to assess whether protein synthesis rates 
are affected during COPD.
Besides muscle wasting also other factors, such as a 
decrease in maximal neural drive to the working muscles 
(Rutherford et al 1986) may contribute to muscle weakness 
during COPD. Indeed, a reduced neural drive may well 
explain the decline in force generating capacity per muscle 
cross-sectional area (speciﬁ  c tension) in vivo without a 
change in in-vitro speciﬁ  c tension of isolated bundles from 
the same muscle (Debigare et al 2003). However, COPD 
patients who were matched for fat free mass index with 
control subjects did not show signs of muscle weakness or 
atrophy (Heijdra et al 2003; Degens et al 2005) indicating 
that the neural drive is maintained as long as fat free mass 
index is maintained.
Contractile properties and ﬁ  ber
type composition
During daily life most activities involve shortening contrac-
tions which require a sufﬁ  cient power output from the muscle. 
Therefore, power output, which is the product of force and 
velocity, is more important during daily life than the ability 
of the muscle to generate isometric force. The loss of power 
in patients with COPD (Yquel et al 2006) as a result of a 
loss in muscle strength may be compensated for, to some 
extent, by the slow-to-fast transition in ﬁ  ber type composition 
(Jobin et al 1998; Gosker, van Mameren et al 2002) and an 
increased proportion of hybrid ﬁ  bers expressing more than 
one myosin heavy chain isoform (Gosker, van Mameren et al International Journal of COPD 2007:2(3) 291
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2002). The slow-to-fast transition appears to be more marked 
during emphysema than in chronic bronchitis (Gosker, van 
Mameren et al 2002) and to be related to the severity of the 
disease in terms of FEV1 (Satta et al 1997). Apart from a 
marked type IIX ﬁ  ber atrophy and a slight increase in ﬁ  brosis 
and fat-cell replacement, which is not uncommon for skeletal 
muscle in the elderly, there are no myopathologic features 
in non-cachetic COPD patients (Gosker, Kubat et al 2003). 
Nevertheless, it is unlikely that the changes in ﬁ  ber type 
composition during COPD, a disease that mostly becomes 
manifest after the age of 50, are just a reﬂ  ection of the age-
ing process as normal ageing is, if anything, accompanied 
by a fast-to-slow rather than a slow-to-fast transition (Narici 
et al 1991; Degens and Alway 2006; Korhonen et al 2006). 
Although the changes in ﬁ  ber type composition during COPD 
may be too small to affect the rates of contraction and relax-
ation during electrically evoked isometric tetani (Degens et al 
2005), it remains to be established whether the ﬁ  ber type 
transition is sufﬁ  cient to cause a change in the shortening 
velocity during dynamic contractions. Nonetheless, as type 
II ﬁ  bers are less efﬁ  cient than type I ﬁ  bers for force genera-
tion (Stienen et al 1996), the slow-to-fast-transition in ﬁ  ber 
type composition may at least partly explain the reduced 
mechanical efﬁ  ciency of COPD patients during one leg knee 
extensor exercise (Franssen, Wouters, Baarends et al 2002; 
Richardson et al 2004).
Metabolism and capillarization
Several studies have addressed the metabolic characteristics 
of muscles from COPD patients (Jakobsson et al 1990, 1995; 
Jobin et al 1998; Whittom et al 1998; Gosker, van Mameren 
et al 2002). The results of these studies are equivocal. Part of 
the discrepancies in the literature can be ascribed to differ-
ences in disease severity, medication (see section medication) 
and whether locomotor or other muscles have been studied. 
While the oxidative capacity of the vastus lateralis muscle 
of patients with moderate-to-severe COPD was signiﬁ  cantly 
reduced (Jakobsson et al 1995; Gosker, van Mameren et al 
2002), the oxidative capacity in the musculature of the upper 
extremity was not affected (Gea, Pasto et al 2001). Also, 
the mechanical efﬁ  ciency was lower in leg muscles, while 
arm mechanical efﬁ  ciency was not signiﬁ  cantly affected 
(Franssen, Wouters, Baarends et al 2002). The different 
effect that COPD has on upper body and leg muscles was 
so marked that it is referred to as ‘the compartment theory’ 
(Gea, Orozco-Levi et al 2001). A simple explanation put 
forward for the differences between the two ‘compartments’ 
is the different degree of disuse they experience during 
COPD (Gosselink et al 2000; Gea, Orozco-Levi et al 2001). 
Nevertheless, the glycolytic capacity was elevated in both 
the muscles of the leg (Jakobsson et al 1995) and the upper 
body (Gea, Pasto et al 2001). In advanced stages of the 
disease, however, energy metabolism becomes increasingly 
compromised as reﬂ  ected by lower levels of glycogen, ATP 
and PCr in the quadriceps femoris muscle of patients with 
respiratory failure, but not in those without respiratory failure 
(Jakobsson et al 1990).
Little work has yet been done on the capillarization of 
skeletal muscle in COPD (Jobin et al 1998; Whittom et al 
1998; Richardson et al 2004). Although the number of cap-
illaries per ﬁ  ber might be reduced during COPD (Whittom 
et al 1998), the capillary supply per ﬁ  ber CSA and total 
numerical capillary density was maintained (Whittom et al 
1998). It seems that, at least anatomically, the microcircula-
tion is intact in COPD patients (Richardson et al 2004). This 
is not an unequivocal ﬁ  nding, however, as Jobin et al (1998) 
found an almost 50% decrease in capillary to ﬁ  ber ratio and 
capillary density, suggesting that a disproportionate loss of 
capillaries may occur during COPD.
Skeletal muscle fatigue
Muscle fatigue can be deﬁ  ned as the inability of a muscle to 
maintain a certain force or power output. As has been 
mentioned above exercise intolerance, as reﬂ  ected by a 
low peak oxygen uptake, is a major symptom in patients 
with COPD (Oga et al 2007). It is likely that the increased 
load and oxygen need of the respiratory muscles during 
COPD and reduced venous return compete with an impaired 
delivery of oxygen to the limb muscles (Aliverti and 
Macklem 2001). However, under circumstances where the 
cardio-respiratory system is unlikely to be the limiting fac-
tor, such as during one-leg exercise, or exercise of a single 
muscle or muscle group, the capillarization and oxidative 
capacity of a muscle are important determinants of muscle 
fatigue resistance (Degens and Veerkamp 1994). Therefore, 
it is no surprise in light of these changes in the muscle as 
described above that an increased susceptibility to skeletal 
muscle fatigue has often been reported in COPD patients 
(Serres et al 1998; Allaire et al 2004; Coronell et al 2004; 
Van’t Hul et al 2004; Saey et al 2005; Janaudis-Ferreira 
et al 2006). Other studies, however, do report an unaltered 
fatigue resistance (Gosker, Lencer et al 2003; Degens et al 
2005; Franssen et al 2005).
Besides changes in the muscle itself that may cause an 
earlier onset of muscle fatigue, changes in fatigue resistance 
could also be caused by an altered central drive (central International Journal of COPD 2007:2(3) 292
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fatigue) (Bigland-Ritchie et al 1978). To date, the central 
component in the development of muscle fatigue in COPD 
patients is poorly understood. However, it may play a role 
in the development of fatigue as systemic inﬂ  ammation has 
been shown to cause feelings of tiredness (Spath-Schwalbe 
et al 1998). However, muscle fatigability has been determined 
largely with series of voluntary contractions (Serres et al 
1998; Coronell et al 2004; Van’t Hul et al 2004; Janaudis-
Ferreira et al 2006), which makes it difﬁ  cult to differentiate 
between central and peripheral factors. Using electrical 
or magnetic stimulation, however, one can exclude the 
contribution of central factors to the development of fatigue. 
As far as we know, only one study (Degens et al 2005) has 
assessed peripheral muscle fatigue using electrical stimula-
tion in patients with COPD. In that study, neither differences 
in contractile properties nor fatigability were found. This 
indicates that there were no apparent differences in moti-
vation between patients and controls matched for fat free 
mass index and physical activity level (Degens et al 2005). 
Although it is thus possible that the alterations in fatigue 
resistance observed in other studies may be related to a lower 
fat free mass index in patients with COPD and controls, the 
observation that muscle endurance was similar in wasted and 
non-wasted patients (Gosker, Lencer et al 2003; Franssen 
et al 2005) argues against this. However, in several studies 
it has been explicitly stated that the COPD patients were 
signiﬁ  cantly less active than the controls (Serres et al 1998; 
Coronell et al 2004). Clearly, at least part of the decline in 
fatigue resistance often observed during COPD is attributable 
to a reduced physical activity level, but also smoking itself 
may reduce muscle fatigue resistance (Wüst et al 2006).
Factors underlying muscle 
dysfunction and wasting
Many factors have been suggested to induce changes in skeletal 
muscle structure and function in COPD. Here we will summa-
rize the possible role of airﬂ  ow obstruction, disuse, hypoxemia, 
malnutrition, oxidative stress and systemic inﬂ  ammation in the 
adaptations of skeletal muscle of patients with COPD. Figure 
1 summarizes how disuse, hypoxia and systemic inﬂ  ammation 
may affect muscle wasting and dysfunction in COPD.
Airﬂ  ow obstruction
In the GOLD classiﬁ  cation the severity of COPD is deter-
mined as the degree of airﬂ  ow obstruction as indicated by 
the percentage of the predicted FEV1. Despite the fact that a 
low FEV1 indicates a severe case of COPD no correlations 
between FEV1 and skeletal muscle strength or fatigue have 
been observed (Gosker, Kubat et al 2003; Gosker, Lencer 
et al 2003; Degens et al 2005). In terms of muscle fatigability, 
this is not surprising, as during muscle fatigue tests a rela-
tively small muscle mass is recruited of which the oxygen 
requirement is well within the limits that can be provided by 
the affected lung. Although, the increased cost of breathing 
as a result of the obstructive airﬂ  ow may well be a cause of 
exercise intolerance during COPD (Aliverti and Macklem 
2001) and may cause structural changes in the respiratory 
muscles due to the continuous overload (Orozco-Levi et al 
2001), it seems unlikely that the airﬂ  ow obstruction per se 
will affect peripheral skeletal muscle structure or function.
Disuse
The physical activity level of patients with COPD is lower 
than that of the average population (Pitta et al 2005, 2006b) 
and during and after a period of exacerbations patients 
become even less active (Pitta et al 2006a). This is thought 
to be a consequence of the so-called dyspnea spiral: patients 
do not exert themselves too much in order to avoid the occur-
rence of dyspnea, which in turn causes a decline in ﬁ  tness 
and an earlier occurrence of dyspnea and so on (Serres et al 
1998). It is therefore not surprising that disuse contributes 
signiﬁ  cantly to the alterations in skeletal muscle structure and 
function during COPD (Degens and Alway 2006). In fact, 
in a patient group compared with a physical activity level 
matched control group, no differences in muscle strength, 
fatigue resistance and contractile properties were detected 
(Degens et al 2005). However, disuse alone is inadequate to 
explain all the changes occurring in skeletal muscle structure 
and function. For instance, Gosker et al (Gosker, Engelen 
et al 2002) showed that atrophy mainly occurred in type IIX 
ﬁ  bers, whereas disuse would cause atrophy of each ﬁ  ber type, 
with type I ﬁ  bers being affected the most (Degens and Alway 
2006). Also, a 12-weeks physical-rehabilitation program did 
not entirely reverse the effects of COPD in terms of capil-
larization and ﬁ  ber type distribution (Whittom et al 1998).
Hypoxemia
Due to the difﬁ  culties with breathing and impaired oxygen 
uptake, patients with severe COPD may have a decreased 
hemoglobin oxygen saturation level (hypoxemia), which 
may result in local tissue hypoxia. The abundance of the 
transcription factor hypoxia-inducible factor-1α (HIF-1α) 
increases during hypoxia (Raguso et al 2004) and may induce 
a down-regulation of oxidative enzymes and an upregulation 
of glycolytic enzymes (Hoppeler et al 2003). In addition, it 
has been shown in cardiomyocytes that hypoxia inactivates International Journal of COPD 2007:2(3) 293
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the transcription factor peroxisome proliferator-activated 
receptor α (PPARα) and thereby decreases the expression 
of genes involved in fatty acid oxidation (Huss et al 2001). 
These changes in transcriptional regulation of the expression 
of metabolic genes during hypoxia may result in an increased 
glycolytic and a reduced oxidative capacity similar to what 
is observed during COPD (Hoppeler et al 2003; Raguso 
et al 2004).
Chronic hypoxia may be linked with muscle wasting 
and weakness. Just 8 weeks at altitudes greater than 5000 
m has been shown to cause as much as a 10% reduction in 
muscle mass and peak power (Ferretti et al 1990; Hoppeler 
et al 1990). Although a decrease in ﬁ  ber CSA is associated 
with exposure to hypoxia (Hoppeler et al 1990; MacDougall 
et al 1991), other confounding factors such as a decreased 
food intake, due to an hypoxia-induced expression of leptin, 
together with detraining may contribute to muscle wasting 
during hypoxia (Westerterp and Kayser 2006).
Hypoxia has been shown to impair the mTOR pathway, 
which is involved in transcription of DNA and translation 
of mRNA into protein (Proud 2004b) and may, as a conse-
quence, contribute to muscle wasting during COPD. In addi-
tion, it has been reported in cell culture studies that hypoxia 
inhibits myoblast differentiation by degradation of MyoD, 
a myogenic transcription factor, via the ubiquitin proteasome 
pathway (Di Carlo et al 2004). Clearly, such an effect in vivo 
will have a negative impact on the regenerative potential of 
skeletal muscle. Moreover, hypoxia may also induce inﬂ  am-
mation (Orth et al 2005), causing muscle atrophy through 
inﬂ  ammatory pathways (see below and Figure 1).
In addition to these relatively long-term effects, there is 
evidence that hypoxia might acutely affect the contractile 
apparatus. Indeed, single ﬁ  bers isolated from bundles exposed 
to hypoxia for 30 min exhibited a marked force loss which 
was attributable to a reduced fraction of strongly attached 
cross bridges, while reoxygenation completely reversed 
the contractile dysfunction (Ottenheijm, Heunks, Geraedts 
et al 2006). In addition to muscle weakening, hypoxia has 
also been shown to reduce the maximum shortening veloc-
ity, power output, force frequency relation and endurance 
in muscle bundles (Machiels et al 2001; Zhu et al 2005), 
possibly through nitrotyrosylation of proteins (Ottenheijm, 
Hypoxia
ROS
HIF-1α
TNF-α
TNF-α
Skeletal muscle dysfunction and wasting
Glycolysis
Disuse
NF-κB
Ubiquitin proteasome Apoptosis Id proteins
Low MRFs
Impaired differentiation / regeneration
mTOR impaired
Impaired protein 
synthesis
Figure 1 Pathways by which hypoxia, disuse and systemic inﬂ  ammation contribute to muscle dysfunction and wasting during Chronic Obstructive Pulmonary Disease. Grey 
shaded boxes indicate impaired regeneration or protein synthesis; black shaded box represents the end result of the pathways in terms of muscle dysfunction and muscle 
wasting. Solid lines indicate observed relations; dotted lines indicate possible relations. TNF-α: tumor necrosis factor - α; mTOR: mammalian target of rapamycin; ROS: 
reactive oxygen species; HIF-1α: hypoxia-inducible factor - 1α; NF-κB: nuclear factor - κB; Id proteins: inhibitor of differentiation proteins; MRFs: myogenic regulatory factors 
(such as MyoD).International Journal of COPD 2007:2(3) 294
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Heunks, Geraedts et al 2006) and the presence of reactive 
oxygen species (ROS). Although in vitro there seems to be 
a clear effect of acute hypoxia on skeletal muscle function 
this is not necessarily the case in vivo. In the electrically 
stimulated human quadriceps muscle no change in contractile 
properties, strength or fatigue resistance could be detected 
during acute exposure to hypoxia (Degens et al 2006). The 
discrepancy between in vitro and in vivo observations might 
be caused by absence of oxidative stress in vivo (Dousset 
et al 2002). It is possible that hemoglobin and myoglobin, 
absent in the in vitro situation, scavenge nitric oxygen (NO) 
and ROS, so that the detrimental effects of these substances 
are attenuated, at least for a limited period (Ordway and 
Garry 2004). Indeed, in chronic hypoxemic COPD patients 
oxidative stress is enhanced (Koechlin et al 2005).
Hypoxia itself, however, can not fully account for all the 
observed changes in skeletal muscle as many patients with 
COPD suffering from muscle wasting and dysfunction do 
not exhibit hypoxemia. In addition, hypoxia may even pro-
tect the nucleus from apoptosis (Riva et al 2001), whereas 
an elevated occurrence of apoptosis in skeletal muscle has 
been observed in depleted patients with COPD (Agusti et al 
2002; Degens et al submitted).
Malnutrition
Many patients with COPD suffer from semi-starvation, 
possibly caused by elevated levels of circulating leptin, 
which negatively affects dietary intake and consequently 
muscle mass and function (Engelen et al 1994; Casaburi 
2001; Franssen, Wouters, Schols 2002; Schols 2003a). 
Moreover, the basal metabolism in COPD is increased as 
a consequence of extra work required for breathing and/or 
the presence of systemic inﬂ  ammation. Hypermetabolism 
in combination with a decreased appetite often leads to 
a negative nutrition balance and ultimately weight loss 
(Schols 2003b).
Oxidative stress
Reative Oxygen Species (ROS) and free radicals are 
elevated in patients with COPD both during rest and exercise 
(Couillard et al 2002, 2003; Gosker, Bast et al 2005; van Hel-
voort, Heijdra, Thijs 2006). The mitochondrial electron trans-
port chain and neutrophils are an important source of ROS 
(Zhang et al 1990). Also hypoxia, cigarette smoke, sepsis and 
an increased cost of breathing (Heunks and Dekhuijzen 2000) 
cause an increased generation of ROS and reactive nitrogen 
species in the lungs and respiratory muscles, spilling into 
the circulation. There is evidence that an abnormal oxidative 
stress response to submaximal and maximal exercise may 
be more severe in muscle-wasted than non-muscle-wasted 
patients with COPD (van Helvoort, Heijdra, Thijs 2006). 
Oxidative stress may acutely affect skeletal muscle func-
tion via inhibition of the activity of the sodium/potassium 
pump (Comellas et al 2006), sarcoplasmic reticulum function, 
myosin ATPase and mitochondrial respiration (Zhang et al 
1990), and in the long run may also cause muscle wasting 
and dysfunction in both respiratory and peripheral muscle 
(Langen et al 2003; Koechlin et al 2004, 2005 Ottenheijm, 
Heunks, Geraedts et al 2006).
Systemic inﬂ  ammation
A common feature in many chronic diseases including 
COPD is the presence of systemic and/or local inﬂ  amma-
tion (Gan et al 2004). In patients with COPD the lung is 
thought to be the main source of inﬂ  ammatory cytokines. 
It has been shown that resistive breathing may cause the 
respiratory muscles also to produce inﬂ  ammatory cytokines 
and thereby to contribute to the development of cachexia 
in patients with COPD (Vassilakopoulos et al 2004). The 
negative correlation between muscle strength and a marker 
of systemic inﬂ  ammation during an exacerbation (Spruit 
et al 2003) suggests that inﬂ  ammation is indeed an impor-
tant factor in muscle adaptations during COPD (Degens 
and Alway 2006).
Inﬂ  ammatory cytokines may also have central actions 
leading to “sickness behavior”, a loss of motivation and thus 
contribute to tiredness and the downward spiral of inactivity 
(Spath-Schwalbe et al 1998). For instance, acute administra-
tion of IL-6 to otherwise healthy trained runners seriously 
impaired exercise performance (Robson-Ansley et al 2004), 
but the effect may be mediated by an altered (serotonergic) 
activity in the brain increasing the sensation of generalized 
fatigue (the central fatigue hypothesis), rather than peripheral 
factors (Polkey 2003).
In the remainder of this section we will concentrate 
mainly on the effects of TNF-α on skeletal muscle tissue, 
as most research has focused on this cytokine. Cachectin, 
or TNF-α, has long been known to induce muscle wasting 
(Beutler and Cerami 1986). In a transgenic mouse model 
that over-expresses TNF-α in the lung, not only circulating 
TNF-α levels, but also the expression of TNF-α in the muscle 
were increased; the latter was thought to be the result of 
TNF-α inducing its own expression via a positive feed back 
loop (Langen et al 2006). One can imagine, that in particular 
during exacerbations, when the inﬂ  ammation is aggravated 
(Papi et al 2006), this is a serious complication.International Journal of COPD 2007:2(3) 295
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TNF-α may also have acute effects on skeletal muscle 
function. For instance, systemic administration of TNF-α 
to dogs caused diaphragm weakness after only three hours 
(Wilcox et al 1994). Since then, it has been shown in vitro 
that exposure of single muscle ﬁ  bers to TNF-α decreased the 
force generating capacity (Li et al 2000; Reid et al 2002), 
possibly through the generation of ROS or reactive nitrogen 
species. It should be noted, however, that in these studies 
supraphysiological doses of TNF-α were applied and it 
remains to be determined whether physiological levels of 
TNF-α have similar effects.
Chronically elevated systemic inﬂ  ammation increases the 
activity of the ubiquitin proteasome pathway via activation 
of nuclear factor – κB (NF-κB), a factor that plays an impor-
tant role in muscle atrophy (Debigare et al 2001; Kandarian 
and Jackman 2006). The ubiquitin proteasome pathway 
is an ATP-dependent protein degradation pathway where 
proteins are labeled by ubiquitin for subsequent degradation 
in the proteasome. Although the activation of the ubiqui-
tin-proteasome pathway is apparent in many other chronic 
diseases, including cancer (Khal et al 2005), it is not known 
whether activation of the ubiquitin-proteasome pathway also 
plays a role in peripheral skeletal muscle wasting during 
COPD. Only recently it has been shown that the ubiquitin-
proteasome pathway is activated in the diaphragm in patients 
with mild-to-moderate COPD (Ottenheijm, Heunks, Li et al 
2006) leading to a loss of myosin, and thereby force generat-
ing capacity (Ottenheijm et al 2005).
Besides activating the ubiquitin proteaseome pathway 
TNF-α induces apoptosis, or programmed cell death, in 
skeletal muscle cells and myoblasts (Bazzoni and Beutler 
1996; Stewart et al 2004). The loss of myonuclei may 
cause an increase of the myonuclear domain, the volume 
of cytoplasm associated with a single myonucleus, beyond 
a sustainable size and consequently be followed by muscle 
ﬁ  ber atrophy (Allen et al 1999). Apoptosis may indeed 
play a role in muscle wasting during COPD in particular 
in patients with a low body mass index (Agusti et al 2002; 
Plataki et al 2006). In addition, TNF-α induces expression 
of Id proteins in astrocytes (Tzeng et al 1999) and Id proteins 
in turn can induce apoptosis both via alteration of gene 
transcription and binding to regulators of apoptosis (Florio 
et al 1998). Although a link between TNF-α and Id protein 
expression has not been investigated in other cell types, Id 
proteins themselves have been shown to induce apoptosis 
in many cell types, including neonatal cardiomyocytes and 
myoblasts (Yokota and Mori 2002). It is therefore tempting 
to speculate that altered Id expression also plays a role in 
the development of apoptosis during COPD and impaired 
regenerative capacity. This has not yet been investigated in 
patients with COPD, but both the elevated expression of Id2 
protein and apoptotic factors in the diaphragm and soleus 
of the emphysematous hamster (Alway et al 2004) hint to 
this possibility.
As mentioned above, it is possible that the primary 
problem of muscle atrophy during COPD is a decreased 
regenerative capacity. Myogenic regulatory factors, such as 
MyoD, play an important role in satellite cell differentiation 
and hence regenerative capacity of the muscle (Charge et al 
2004). Both in transgenic mice overexpressing TNF-α in the 
lung (Langen et al 2006) and in mice treated with TNF-α 
(Guttridge et al 2000; Langen et al 2004), the regeneration of 
skeletal muscle from disuse atrophy is delayed. This decline 
in regenerating capacity was possibly related to an acceler-
ated breakdown of MyoD by the ubiquitin proteasome path-
way (Langen et al 2004). Interestingly, MyoD becomes more 
prone to degradation by the ubiquitin proteasome pathway 
when it forms dimers with inhibitors of differentiation (Id) 
proteins (Reid 2005). Elevation of these proteins may thus 
contribute to the reduced abundance of MyoD protein but 
not mRNA in the soleus and diaphragm of emphysematous 
hamsters (Degens et al 2004), indicating MyoD breakdown 
rather than reduced transcription. No studies have so far 
investigated whether alterations in MyoD and Id expression 
also occur in skeletal muscle from patients with COPD and 
whether they also suffer from an impaired skeletal muscle 
regenerative capacity.
Rehabilitation and medication
Here we only brieﬂ  y discuss several of the more common 
potential treatments that target skeletal muscle wasting during 
COPD. For a more extensive discussion we refer the reader 
to other reviews that speciﬁ  cally address this issue (Spruit 
et al 2004; Hansen et al 2006).
Exercise training
As disuse is considered an important factor contributing to 
muscle wasting and dysfunction it is not surprising that many 
studies have addressed the efﬁ  cacy of exercise training on 
skeletal muscle structure and function in patients with COPD 
(Serres et al 1998; Franssen et al 2005; Gosker, Schrauwen 
et al 2005).
Endurance training improves exercise tolerance in 
patients with moderate and severe COPD, with the effect 
being largely inﬂ  uenced by the intensity of the training; a 
low intensity produces less of an effect than high intensity International Journal of COPD 2007:2(3) 296
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training sessions (Casaburi 2001). This improvement in 
exercise tolerance is accompanied by at least a reduction of 
the percentage of type II ﬁ  bers, muscle hypertrophy and an 
increase in oxidative capacity (Whittom et al 1998; Casaburi 
2001; Vogiatzis et al 2005).
Strength training is effective in increasing muscle mass 
and strength and is associated with an improved quality 
of life in patients with COPD (Casaburi 2001). Combined 
strength/endurance training results in the beneﬁ  ts that each 
of the programs separately would achieve, ie, not only an 
increase in submaximal exercise capacity, but also improve-
ments in lean body mass and strength (Ortega et al 2002). 
Moreover, interval training might also be preferred above 
constant-load exercise as it minimizes leg discomfort and 
ratings of dyspnea, without compromising the beneﬁ  ts of the 
endurance training program (Vogiatzis et al 2005).
This response to training represents a normal response of 
the muscle to increased use (Salmons and Henriksson 1981). 
The beneﬁ  cial effects of exercise may, at least partly, be 
brought about by an increase in the expression of myogenin 
(Siu, Donley et al 2004), a reduction of the occurrence of 
apoptosis (Siu, Bryner et al 2004), and suppression of the 
muscle speciﬁ  c ubiquitin ligase atrogin (Leger et al 2006). 
Furthermore, endurance training may attenuate systemic 
inﬂ  ammation (Garrod et al 2007) and it is thus possible that 
the beneﬁ  cial effects of training are partly mediated via a 
reduction in inﬂ  ammation. So far, it is not clear whether all 
patients would beneﬁ  t from exercise programs as for instance 
in some elderly people the hypertrophic response is attenu-
ated, indicating a reduced plasticity at old age (Welle et al 
1996; Degens and Alway 2006). This attenuated response has 
been shown to be related to elevated baseline levels of soluble 
TNF-receptors in the elderly (Bruunsgaard et al 2004). This 
would imply that chronic patients with a signiﬁ  cantly elevated 
systemic inﬂ  ammation may have reduced improvements in 
response to exercise training, particularly when one consid-
ers that the inﬂ  ammatory and oxidative stress response is 
augmented in muscle-wasted patients (van Helvoort, Heijdra, 
Dekhuijzen 2006). Supporting the notion that exercise may 
loose its effectiveness when systemic inﬂ  ammation is pres-
ent, is the observation that the cellular protein breakdown 
in patients with a low fat free mass does not decline after an 
exercise training regime (Bolton et al 2006).
Nutrition
Nutritional support has been shown to result in functional 
improvements and decreased mortality in depleted patients 
(Schols 2003b). One of the beneﬁ  ts of nutritional support is 
an increase in muscle strength (Efthimiou et al 1988), which 
will inevitably improve the quality of life of the patient. 
Combination of nutritional support and exercise training may 
be the best approach to obtain functional improvements in 
patients with COPD (Schols 2003a). For detailed informa-
tion about the effects of nutrition of muscle performance in 
patients with COPD and other chronic diseases, the reader 
is referred to some excellent reviews on this subject (Schols 
2003b; Engelen et al 2005).
Oxygen therapy
Oxygen supplementation is often used to reduce dyspnea 
experienced by severe hypoxemic COPD patients. Oxygen 
supplementation may not only increase the exercise capacity 
(Aliverti and Macklem 2001), but also reduce the normal 
exercise-induced elevation in systemic inﬂ  ammation and 
oxidative stress in muscle-wasted patients with COPD (van 
Helvoort, Heijdra, Heunks 2006). An additional beneﬁ  t of 
supplemental oxygen during exercise is that patients can 
exercise at higher work loads (Emtner et al 2003) and thereby 
augment the improvement in exercise tolerance.
Long-term oxygen supplementation only beneﬁ  ts hypox-
emic, but not normoxemic patients with COPD by increas-
ing survival and attenuating the progression of pulmonary 
hypertension (Zielinski 1999). However, to our knowledge 
no studies have addressed the direct or long-term effects of 
oxygen therapy on skeletal muscle adaptations in COPD 
patients.
Medication
Anabolic hormone, such as testosterone, supplementation 
has been suggested to treat muscle wasting and dysfunction 
during COPD (Casaburi et al 2004; Hansen et al 2006). 
Combination of strength training and testosterone supple-
mentation appeared to give additive effects on lean body 
mass and strength in patients with COPD (Casaburi et al 
2004). However, the long-term (side and beneﬁ  cial) effects 
of hormone replacement remain to be established. The 
observation that IGF-I is only positively related to muscle 
strength when IL-6 levels are low but not when IL-6 levels 
are high (Barbieri et al 2003) suggests that the effectiveness 
of testosterone replacement (which probably acts in part 
through an effect on IGF-1) may be attenuated in patients 
with high levels of systemic inﬂ  ammation.
Since systemic inﬂ  ammation plays an important role 
in the progression of the disease anti-inﬂ  ammatory drugs 
have been used to attenuate the disease progression and 
the concomitant observed muscle wasting (Hansen et al International Journal of COPD 2007:2(3) 297
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2006). Corticosteroids are often prescribed to minimize the 
inﬂ  ammatory reaction, in particular following exacerbations. 
Unfortunately, corticosteroids also induce the activity of the 
ubiquitin proteasome pathway (Tisdale 2005) and prolonged 
treatment with corticosteroids results in a ‘steroid myopa-
thy’, characterized by a preferential type II ﬁ  ber atrophy 
(Decramer et al 1996). The vitamin D analogue α-calcidol, 
already widely used for the treatment of osteoporosis, has 
proved successful in reducing circulating TNF-α levels and 
the release of cytokines by macrophages and improving 
muscle power in patients with rheumatoid arthritis (Scharla 
et al 2005). No studies have so far addressed the efﬁ  cacy 
of α-calcidol in the treatment of muscle weakness (and/or 
osteoporosis) in COPD.
One could also consider to provide supplementation with 
IGF-I, or inhibitors of TNF-α, but IGF-I may increase the 
chance of getting cancer and TNF-α inhibitors increase the 
risk of sepsis and infection (Hansen et al 2006). Therefore, 
factors downstream, such as the ubiquitin proteasome path-
way, or factors involved in satellite cell differentiation, may 
be better targets. In this context it is worthwhile to note that 
Id proteins may be an interesting target as they play a role in 
muscle wasting and their inhibition is also a potential target 
in the treatment of cancer (Benezra et al 2001).
Drugs that inhibit NF-κB, which is downstream of the 
TNF-receptor and an upstream regulator of MuRF1, a ubiq-
uitin ligase, appear to be effective in attenuating muscle 
wasting during cachexia (Tisdale 2005). Indeed, there are 
clear indications for further drug developments such as 
with inhibitors of the ubiquitin-proteasome pathway and 
apoptosis (Libera and Vescovo 2004; Tisdale 2005; Hansen 
et al 2006). As suggested by Tisdale (2005), it is advisable 
to combine inhibitors of protein degradation with stimula-
tors of protein synthesis by, for instance, an increased intake 
of amino acids, such as leucine, that stimulate the mTOR 
pathway (Proud 2004a).
In clinical settings, it seems that a combination of mul-
tiple strategies results in the best functional improvements. 
Clearly, however, more studies are needed to determine the 
best combination of therapies in terms of cost-effectiveness, 
beneﬁ  t and patient compliance (Schols 2003a).
Summary and conclusion
In this article, we present an overview of the changes in 
muscle structure and function in COPD and the factors 
contributing to these changes are discussed. Muscle wasting 
should be considered as a serious complication in COPD and 
has important implications for survival. One notable feature 
of the literature is the great diversity of muscle symptoms 
in patients with apparently similar degrees of lung disease. 
Whether this indicates a difference in the nature of the 
disease or of the genetic susceptibility to muscle compli-
cations remains an important question. There is no doubt, 
however, that continued research into the question of muscle 
wasting and decreased skeletal muscle fatigue resistance in 
COPD will eventually lead to the development of speciﬁ  c 
treatments for cachexia, such as targeting the ubiquitin 
proteasome pathway, cytokine inhibition, administration 
of anabolic factors as well as life style changes, such as 
exercise and nutrition. The clinical approach to cachexia in 
COPD and other chronic diseases should change dramati-
cally in the near future.
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